First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

NCT07752121 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Neoplasms

Interventions

DRUG: Luspatercept

Sponsor

Bristol-Myers Squibb